BEIGF:OTCMKTS
BeOne Medicines
21,95 USD
0,00%
(0,00) 1 d.
9. 6., 12:49:46 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BEIGF…
Trh. kap.
42,86 mld.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
24,92 USD
Min. za 52 týž.
21,95 USD
Beta
0,84
Akcie v obehu
1,43 mld.
Počet zamestnancov
12 tis.
Trh. kap.
42,86 mld.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
24,92 USD
Min. za 52 týž.
21,95 USD
Beta
0,84
Akcie v obehu
1,43 mld.
Počet zamestnancov
12 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
GlobeNewswire
·
pred 8 minútami
Owlting Group (NASDAQ: OWLS) and Decaf Open U.S. Dollar Accounts Beyond the United States on OwlPay Harbor
StockStory
·
pred 36 minútami
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
Investor's Business Daily
·
pred 37 minútami
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
pred 2 hodinami
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Informácie o subjekte BeOne Medicines
Generálny riaditeľJohn Vincent Oyler | John Vincent Oyler
Zamestnanci12 tis.
Dátum založenia28. 10. 2010
Hlavné sídlo-
Odvetvie-